Denali Therapeutics (DNLI) stock
Follow DNLI's trial news. Pro members can get an alert when Denali Therapeutics files news, and see its trials, share raises, and its CEO's filings.
What's next for DNLI, and how long its cash lasts
From Denali Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 8 quarters
Dilution on the horizon
- Shelf registration (S-3ASR, filed Feb 27, 2025)
- At-the-market share sales program (S-3ASR, filed Feb 27, 2025)
Insiders
Chief Medical Officer Peter Scott Chin sold 1,654 shares on Sep 4. 5 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 28 daysINOInovio Pharmaceuticals
INOINO-3107
- In 39 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 51 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 20% in 3 months, 10% under its 50-day average. Down 59% over 5 years, while the S&P 500 rose 78%.
Down more than its industry: the 275 other stocks in it fell a median 11% over the same 3 months.
−2Long-term trend below a falling 200-day average, down over two years
2 more things pulling DNLI's score down, for Pro members
What's next
Expected to report Thu Nov 5, after the close
After its last 4 reports it closed +0.8% on average, higher 2 of 4 times.
What would turn DNLI's score around: 6 things, for Pro members
Here is what Pro members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
DNLI has 2 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1440.0
- MACD (12, 26, 9)Above signal
- 50-day average$22.93
- 200-day average$21.04
- ADX 1425.8
- Support$19.40
- Resistance$20.55
- Bollinger Bands (20, 2)Inside
- Volume1.1x
How DNLI ranks in Biotech
DNLI is #164 of 276 by Quality Score. The top three are shown with their scores, and more by name.
KNSA7/1418
ABCL6/1416
OABI9/1415
DMRAOpen for its score
DNAOpen for its score
DNTHOpen for its score
DSGNOpen for its score
DNLI2/14-2
When does DNLI report earnings, and what happens after?
Expected to report Thu Nov 5, after the close (in 34 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026After close | After close | +2.8% | +0.4% | +0.4% |
| May 7, 2026After close | After close | -1.4% | -0.5% | -1.6% |
| Feb 26, 2026After close | After close | -1.3% | -1.1% | -8.0% |
| Nov 6, 2025After close | After close | +1.0% | +4.2% | +19.0% |
Who is trading DNLI
DNLI insider trades
2 insiders sold $108K across 2 filings in the last 6 months. No open-market buys on record. The newest:
About Denali Therapeutics
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of DNLI's score, with the points and the reason
- All 14 checks on DNLI and on all 2,958 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on DNLI
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.